VNDA Fundamental Analysis - VANDA PHARMACEUTICALS INC

Fundamental Rating

Overall VNDA gets a fundamental rating of 3 out of 10. We evaluated VNDA against 534 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year VNDA has reported negative net income.

VNDA had a negative operating cash flow in the past year.

VNDA had positive earnings in 4 of the past 5 years.

VNDA had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of VNDA (-10.71%) is better than 83.33% of its industry peers.

VNDA has a Return On Equity of -13.76%. This is amongst the best in the industry. VNDA outperforms 87.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	-10.71%
ROE	-13.76%
ROIC	N/A

ROA(3y)-0.5%

ROA(5y)1.69%

ROE(3y)-0.62%

ROE(5y)1.97%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

VNDA has a better Gross Margin (94.40%) than 94.01% of its industry peers.

VNDA's Gross Margin has been stable in the last couple of years.

VNDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	94.4%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.39%

GM growth 5Y1.12%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for VNDA has been increased compared to 1 year ago.

VNDA has more shares outstanding than it did 5 years ago.

VNDA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.17, we must say that VNDA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of VNDA (1.17) is better than 61.42% of its industry peers.

A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.

VNDA has a Debt to Equity ratio (0.01) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	1.17

ROIC/WACCN/A

WACC9.36%

2.3 Liquidity

A Current Ratio of 3.25 indicates that VNDA has no problem at all paying its short term obligations.

With a Current ratio value of 3.25, VNDA is not doing good in the industry: 61.24% of the companies in the same industry are doing better.

A Quick Ratio of 3.23 indicates that VNDA has no problem at all paying its short term obligations.

VNDA has a Quick ratio of 3.23. This is comparable to the rest of the industry: VNDA outperforms 40.64% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.25
Quick Ratio	3.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -494.74%.

Looking at the last year, VNDA shows a quite strong growth in Revenue. The Revenue has grown by 11.78% in the last year.

Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.64% on average per year.

EPS 1Y (TTM)-494.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475%

Revenue 1Y (TTM)11.78%

Revenue growth 3Y-9.56%

Revenue growth 5Y-2.64%

Sales Q2Q%4.19%

3.2 Future

Based on estimates for the next years, VNDA will show a small growth in Earnings Per Share. The EPS will grow by 6.83% on average per year.

Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 1.13% on average per year.

EPS Next Y-475.88%

EPS Next 2Y-82.36%

EPS Next 3Y6.83%

EPS Next 5YN/A

Revenue Next Year12.81%

Revenue Next 2Y24.69%

Revenue Next 3Y26.56%

Revenue Next 5Y1.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-82.36%

EPS Next 3Y6.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VNDA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (10/21/2025, 1:33:30 PM)

5.325

0 (-0.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)07-31 2025-07-31/bmo

Earnings (Next)10-29 2025-10-29

Inst Owners79.02%

Inst Owner Change-0.28%

Ins Owners7.03%

Ins Owner Change6.65%

Market Cap314.65M

Analysts80

Price Target12.92 (142.63%)

Short Float %8.4%

Short Ratio9.77

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-4.3%

Min EPS beat(2)-26.44%

Max EPS beat(2)17.84%

EPS beat(4)3

Avg EPS beat(4)15.96%

Min EPS beat(4)-26.44%

Max EPS beat(4)45.98%

EPS beat(8)6

Avg EPS beat(8)5.71%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)1.57%

Min Revenue beat(2)-5.56%

Max Revenue beat(2)8.7%

Revenue beat(4)1

Avg Revenue beat(4)-0.51%

Min Revenue beat(4)-5.56%

Max Revenue beat(4)8.7%

Revenue beat(8)3

Avg Revenue beat(8)0.35%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-34.65%

EPS NY rev (1m)0%

EPS NY rev (3m)-20.98%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.12%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.21%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.55
P/FCF	N/A
P/OCF	N/A
P/B	0.65
P/tB	0.84
EV/EBITDA	N/A

EPS(TTM)-1.13

EYN/A

EPS(NY)-1.06

Fwd EYN/A

FCF(TTM)-1.12

FCFYN/A

OCF(TTM)-1.1

OCFYN/A

SpS3.44

BVpS8.23

TBVpS6.36

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-10.71%
ROE	-13.76%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	94.4%
FCFM	N/A

ROA(3y)-0.5%

ROA(5y)1.69%

ROE(3y)-0.62%

ROE(5y)1.97%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.39%

GM growth 5Y1.12%

F-Score3

Asset Turnover0.33

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	13.98%
Cap/Sales	0.55%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.25
Quick Ratio	3.23
Altman-Z	1.17

F-Score3

WACC9.36%

ROIC/WACCN/A

Cap/Depr(3y)14.89%

Cap/Depr(5y)25.49%

Cap/Sales(3y)0.24%

Cap/Sales(5y)0.33%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-494.74%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475%

EPS Next Y-475.88%

EPS Next 2Y-82.36%

EPS Next 3Y6.83%

EPS Next 5YN/A

Revenue 1Y (TTM)11.78%

Revenue growth 3Y-9.56%

Revenue growth 5Y-2.64%

Sales Q2Q%4.19%

Revenue Next Year12.81%

Revenue Next 2Y24.69%

Revenue Next 3Y26.56%

Revenue Next 5Y1.13%

EBIT growth 1Y-210.42%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year7.55%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-263.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-258.43%

OCF growth 3YN/A

OCF growth 5YN/A

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens